HeadlinesNews Stand NG

NAFDAC denies banning Camosunate antimalarial drug in Nigeria

NAFDAC denies banning Camosunate antimalarial drug in Nigeria
Photo courtesy of Nairametrics · Verified via News Stand NG
Source Attribution: Nairametrics

News Stand NG operates under ethical news aggregation guidelines. Source: Nairametrics. To read the unabridged investigative reporting and full gallery, visit the original publication.

Read Full Story on Nairametrics
AI Executive Briefing
Verified Synthesis~90s read
The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed claims circulating on social media that Camosunate, an antimalarial drug, has been banned in Nigeria. The agency disclosed this in a press release dated November 21, 2026, signed by its Director-General, Professor Mojisola Adeyeye.
Context & Background
  • ✦NAFDAC clarified that it has never banned Camosunate or medicines containing the artesunate-amodiaquine combination, while acknowledging that some symptoms highlighted in the viral claims may be associated with known side effects of the drug.
Key Figures & Named Entities
2026:The agency disclosed this in a press release dated November 21, 2026, signed by its Director-General, Professor Mojisola Adeyeye.$6.5 billion:FG partners US firm to establish irrigation equipment factory in NigeriaFlutterwave CEO, Hamzat seek stronger corporate investment in Lagos digital economyBinance secures $6.5 billion court order to recover assets stolen in October hack “The National Agency for Food and Drug Administration and Control (NAFDAC) is refuting claims circulating on social media that Camosunate, an antimalarial medicine containing artesunate and amodiaquine, has been banned in Nigeria.2025:ACPN said the product was registered on November 26, 2025, with its registration valid until November 25, 2030.
Outlook & Next Steps
Follow original publisher reporting for subsequent developments, official responses, and verified updates.
Key Takeaways
Verified Extract
  • ✦The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed claims circulating on social media that Camosunate, an antimalarial drug, has been banned in Nigeria.
  • ✦The agency disclosed this in a press release dated November 21, 2026, signed by its Director-General, Professor Mojisola Adeyeye.
  • ✦NAFDAC clarified that it has never banned Camosunate or medicines containing the artesunate-amodiaquine combination, while acknowledging that some symptoms highlighted in the viral claims may be associated with known side effects of the drug.
Key Facts:2026: The agency disclosed this in a press release dated November 21, 2026, signed by its Director-General, Professor Mojisola Adeyeye.$6.5 billion: FG partners US firm to establish irrigation equipment factory in NigeriaFlutterwave CEO, Hamzat seek stronger corporate investment in Lagos digital economyBinance secures $6.5 billion court order to recover assets stolen in October hack “The National Agency for Food and Drug Administration and Control (NAFDAC) is refuting claims circulating on social media that Camosunate, an antimalarial medicine containing artesunate and amodiaquine, has been banned in Nigeria.2025: ACPN said the product was registered on November 26, 2025, with its registration valid until November 25, 2030.
Editorial Excerpt

The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed claims circulating on social media that Camosunate, an antimalarial drug, has been banned in Nigeria.

Frequently Asked Questions About This Story

What is the latest development regarding Action Peoples Party?

The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed claims circulating on social media that Camosunate, an antimalarial drug, has been banned in Nigeria.

Who are the key organizations or public figures mentioned?

The primary parties identified in this coverage include Action Peoples Party, Lagos State, Ogun State.

What timeline or key figures were confirmed?

The agency disclosed this in a press release dated November 21, 2026, signed by its Director-General, Professor Mojisola Adeyeye.

Related Topics & Entities

More Coverage on This Story